Your browser doesn't support javascript.
loading
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.
Ibraheim, Hajir; Samaan, Mark A; Srinivasan, Ashish; Brain, Oliver; Digby-Bell, Jonathan; Irving, Peter M; Norman, Irena; Jawad, Issrah; Biedermann, Julia; Ibarra, Ana; Kok, Klaartje Bel; Parkes, Gareth; Rimmer, Joanna; Compot, Elisabeta; Parkes, Miles; Segal, Jonathan; Oppong, Philip; Hart, Ailsa; Hayee, Bu'Hussain; Powell, Nick.
Afiliación
  • Ibraheim H; IBD Centre, Guy's and St. Thomas' NHS Foundation Trust, London (Hajir Ibraheim, Mark A. Samaan, Jonathan Digby-Bell, Peter M. Irving, Irena Norman, Nick Powell).
  • Samaan MA; Centre for Inflammation Biology and Cancer Immunology (CIBCI), King's College London (Hajir Ibraheim, Nick Powell).
  • Srinivasan A; IBD Centre, Guy's and St. Thomas' NHS Foundation Trust, London (Hajir Ibraheim, Mark A. Samaan, Jonathan Digby-Bell, Peter M. Irving, Irena Norman, Nick Powell).
  • Brain O; Translational Gastroenterology Unit, Oxford University Hospitals Trust, Oxford (Ashish Srinivasan, Oliver Brain).
  • Digby-Bell J; Translational Gastroenterology Unit, Oxford University Hospitals Trust, Oxford (Ashish Srinivasan, Oliver Brain).
  • Irving PM; IBD Centre, Guy's and St. Thomas' NHS Foundation Trust, London (Hajir Ibraheim, Mark A. Samaan, Jonathan Digby-Bell, Peter M. Irving, Irena Norman, Nick Powell).
  • Norman I; IBD Centre, Guy's and St. Thomas' NHS Foundation Trust, London (Hajir Ibraheim, Mark A. Samaan, Jonathan Digby-Bell, Peter M. Irving, Irena Norman, Nick Powell).
  • Jawad I; IBD Centre, Guy's and St. Thomas' NHS Foundation Trust, London (Hajir Ibraheim, Mark A. Samaan, Jonathan Digby-Bell, Peter M. Irving, Irena Norman, Nick Powell).
  • Biedermann J; Department of Gastroenterology, University College London Hospital, London (Issrah Jawad).
  • Ibarra A; Department of Gastroenterology, King's College Hospital, Denmark Hill, London (Julia Biedermann, Bu'Hussain Hayee).
  • Kok KB; Department of Gastroenterology, Barts Health NHS Trust, London (Ana Ibarra, Klaartje Bel Kok, Gareth Parkes).
  • Parkes G; Department of Gastroenterology, Barts Health NHS Trust, London (Ana Ibarra, Klaartje Bel Kok, Gareth Parkes).
  • Rimmer J; Department of Gastroenterology, Barts Health NHS Trust, London (Ana Ibarra, Klaartje Bel Kok, Gareth Parkes).
  • Compot E; Department of Gastroenterology, Addenbrooke's Hospital, Cambridge (Joanna Rimmer, Elisabeta Compot, Miles Parkes).
  • Parkes M; Department of Gastroenterology, Addenbrooke's Hospital, Cambridge (Joanna Rimmer, Elisabeta Compot, Miles Parkes).
  • Segal J; Department of Gastroenterology, Addenbrooke's Hospital, Cambridge (Joanna Rimmer, Elisabeta Compot, Miles Parkes).
  • Oppong P; St. Mark's Hospital, IBD Unit, Harrow, London (Jonathan Segal, Philip Oppong, Ailsa Hart).
  • Hart A; Division of Integrative Systems Medicine and Digestive disease, Department of Surgery and Cancer, Faculty of medicine, Imperial College London, London (Jonathan Segal, Ailsa Hart), UK.
  • Hayee B; St. Mark's Hospital, IBD Unit, Harrow, London (Jonathan Segal, Philip Oppong, Ailsa Hart).
  • Powell N; St. Mark's Hospital, IBD Unit, Harrow, London (Jonathan Segal, Philip Oppong, Ailsa Hart).
Ann Gastroenterol ; 33(2): 170-177, 2020.
Article en En | MEDLINE | ID: mdl-32127738
BACKGROUND: The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-related complications. However, there is a paucity of data exploring the outcomes of vedolizumab in this group. Our objective was to determine the clinical effectiveness and safety of vedolizumab in older IBD patients within a real-world multicenter UK cohort. METHODS: A retrospective review of electronic records across 6 UK hospitals was undertaken to evaluate the clinical effectiveness and safety outcomes of vedolizumab in IBD patients aged ≥60 at start of therapy. Rates of clinical response, remission and corticosteroid-free remission were assessed at weeks 14 and 52, using validated clinical indices, and were compared to historical controls from real-world vedolizumab-treated cohorts unstratified by age. RESULTS: Of 74 patients aged 60 years or above (median 66 years), 48 were included in our effectiveness analysis (29 ulcerative colitis, 19 Crohn's disease). Rates of clinical response, remission and corticosteroid-free remission at week 14 were 64%, 48% and 30%, respectively. By week 52, the rates of clinical response, remission, and corticosteroid-free remission were 52%, 38%, and 32%, respectively. Six (8%) patients experienced adverse effects. Effectiveness and safety outcomes were comparable to those of age-unstratified vedolizumab-treated cohorts. CONCLUSION: Our 1-year outcome data suggests that vedolizumab is safe and effective in older IBD patients and broadly comparable to cohorts unselected by age.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Gastroenterol Año: 2020 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Gastroenterol Año: 2020 Tipo del documento: Article Pais de publicación: Grecia